Carrier, L., Mearini, G., Stathopoulou, K. & Cuello, F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene 573, 188–197 (2015).
Strande, J. L. Haploinsufficiency MYBPC3 mutations: another stress induced cardiomyopathy? Let’s take a look! J. Mol. Cell. Cardiol. 79, 284–286 (2015).
Feric, N. T. & Radisic, M. Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv. Drug Deliv. Rev. 96, 110–134 (2016).
Mathur, A. et al. In vitro cardiac tissue models: current status and future prospects. Adv. Drug Deliv. Rev. 96, 203–213 (2016).
Eng, G. et al. Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes. Nat. Commun. 7, 10312 (2016).
Turnbull, I. C. et al. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J. 28, 644–654 (2014).
Conradi, L. et al. Immunobiology of fibrin-based engineered heart tissue. Stem Cells Transl. Med. 4, 625–631 (2015).
Legant, W. R. et al. Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues. Proc. Natl Acad. Sci. USA 106, 10097–10102 (2009).
Mathur, A. et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci. Rep. 5, 8883 (2015).
Abramson, S. V. et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann. Intern. Med. 116, 888–895 (1992).
Engler, A. J. et al. Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating. J. Cell Sci. 121, 3794–3802 (2008).
Kijlstra, J. D. et al. Integrated analysis of contractile kinetics, force generation, and electrical activity in single human stem cell-derived cardiomyocytes. Stem Cell Rep. 5, 1226–1238 (2015).
Liau, B., Christoforou, N., Leong, K. W. & Bursac, N. Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. Biomaterials 32, 9180–9187 (2011).
Schaaf, S. et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS ONE 6, e26397 (2011).
Ribeiro, A. J. et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc. Natl Acad. Sci. USA 112, 12705–12710 (2015).
Hirt, M. N. et al. Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res. Cardiol. 107, 307 (2012).
Hinson, J. T. et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349, 982–986 (2015).
Stoppel, W. L., Kaplan, D. L. & Black, L. D.III Electrical and mechanical stimulation of cardiac cells and tissue constructs. Adv. Drug Deliv. Rev. 96, 135–155 (2016).
Kawata, S., Sun, H. B., Tanaka, T. & Takada, K. Finer features for functional microdevices. Nature 412, 697–698 (2001).
Klein, F. et al. Elastic fully three-dimensional microstructure scaffolds for cell force measurements. Adv. Mater. 22, 868–871 (2010).
Jeon, H., Hidai, H., Hwang, D. J. & Grigoropoulos, C. P. Fabrication of arbitrary polymer patterns for cell study by two-photon polymerization process. J. Biomed. Mater. Res. A 93, 56–66 (2010).
Ma, Z. et al. Three-dimensional filamentous human diseased cardiac tissue model. Biomaterials 35, 1367–1377 (2014).
Burridge, P. W. et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855–860 (2014).
Tohyama, S. et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127–137 (2013).
Thavandiran, N. et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc. Natl Acad. Sci. USA 110, E4698–E4707 (2013).
Huebsch, N. et al. Miniaturized iPS-cell-derived cardiac muscles for physiologically relevant drug response analyses. Sci. Rep. 6, 24726 (2016).
Gautel, M., Furst, D. O., Cocco, A. & Schiaffino, S. Isoform transitions of the myosin binding protein C family in developing human and mouse muscles: lack of isoform transcomplementation in cardiac muscle. Circ. Res. 82, 124–129 (1998).
Bennett, P. M., Furst, D. O. & Gautel, M. The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? Rev. Physiol. Biochem. Pharmacol. 138, 203–234 (1999).
Moss, R. L., Fitzsimons, D. P. & Ralphe, J. C. Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium. Circ. Res. 116, 183–192 (2015).
Previs, M. J. et al. Molecular mechanics of cardiac myosin-binding protein C in native thick filaments. Science 337, 1215–1218 (2012).
Lan, F. et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101–113 (2013).
Argenziano, M. et al. Electrophysiologic characterization of calcium handling in human induced pluripotent stem cell-derived atrial cardiomyocytes. Stem Cell Rep. 10, 1867–1878 (2018).
Hidai, H., Jeon, H., Hwang, D. J. & Grigoropoulos, C. P. Self-standing aligned fiber scaffold fabrication by two photon photopolymerization. Biomed. Microdevices 11, 643–652 (2009).
Mandegar, M. A. et al. CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. Cell Stem Cell 18, 541–553 (2016).
Musunuru, K. Genome editing of human pluripotent stem cells to generate human cellular disease models. Dis. Models Mech. 6, 896–904 (2013).
Harris, S. P. et al. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res. 90, 594–601 (2002).
Korte, F. S., McDonald, K. S., Harris, S. P. & Moss, R. L. Loaded shortening, power output, and rate of force redevelopment are increased with knockout of cardiac myosin binding protein-C. Circ. Res. 93, 752–758 (2003).
De Lange, W. J. et al. Neonatal mouse-derived engineered cardiac tissue: a novel model system for studying genetic heart disease. Circ. Res. 109, 8–19 (2011).
Fraysse, B. et al. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J. Mol. Cell. Cardiol. 52, 1299–1307 (2012).
Chen, P. P. et al. Dissociation of structural and functional phenotypes in cardiac myosin-binding protein C conditional knockout mice. Circulation 126, 1194–1205 (2012).
Baumgarten, G. et al. Myocardial injury modulates the innate immune system and changes myocardial sensitivity. Basic Res. Cardiol. 101, 427–435 (2006).
Birket, M. J. et al. Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function. Cell Rep. 13, 733–745 (2015).
Ribeiro, A. J. S. et al. Multi-imaging method to assay the contractile mechanical output of micropatterned human iPSC-derived cardiac myocytes. Circ. Res. 120, 1572–1583 (2017).
McCain, M. L. et al. Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip. Proc. Natl Acad. Sci. USA 110, 9770–9775 (2013).
Yang, H. et al. Dynamic myofibrillar remodeling in live cardiomyocytes under static stretch. Sci. Rep. 6, 20674 (2016).
Hirt, M. N. et al. Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J. Mol. Cell. Cardiol. 81, 1–9 (2015).
Stohr, A. et al. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J. Mol. Cell. Cardiol. 63, 189–198 (2013).
Tanaka, A. et al. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. J. Am. Heart Assoc. 3, e001263 (2014).
Bostrom, P. et al. C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143, 1072–1083 (2010).
Wei, J. Q. et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 118, 934–946 (2008).
He, A., Kong, S. W., Ma, Q. & Pu, W. T. Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart. Proc. Natl Acad. Sci. USA 108, 5632–5637 (2011).
He, A. et al. Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease. Nat. Commun. 5, 4907 (2014).
Dai, Y. S., Cserjesi, P., Markham, B. E. & Molkentin, J. D. The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J. Biol. Chem. 277, 24390–24398 (2002).
Sunagawa, Y. et al. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J. Biol. Chem. 285, 9556–9568 (2010).
Hutter, J. L. & Bechhoefer, J. Calibration of atomic-force microscope tips. Rev. Sci. Instrum. 64, 1868–1873 (1993).
Laughner, J. I. et al. Processing and analysis of cardiac optical mapping data obtained with potentiometric dyes. Am. J. Physiol. Heart C 303, H753–H765 (2012).